KAI Pharmaceuticals announced it has initiated a second Phase 2a study of KAI-1678, an isozyme-selective, small peptide inhibitor of the epsilon protein kinase C pathway (epsilon PKC) for the treatment of chronic neuropathic pain associated with chronic postherpetic neuralgia (PHN). The Phase 2a PHN study is a double-blind, randomized, placebo- and active-comparator-controlled, single-dose, crossover trial designed to evaluate the efficacy of KAI-1678 administered by subcutaneous (SQ) infusion. The primary endpoint of the study is the mean change from baseline in pain intensity scores at the end of drug infusion.

For more information call (650) 244-1100 or visit www.kaipharma.com.